B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis

Conclusion Measurement of brain-reactive B-cell activity by ELISPOT provides clinically meaningful predictive probabilities of individual patients' treatment response to GA or IFN-β. The assay has the potential to improve the selection of optimal first-line treatment for individual patients with RRMS. Classification of Evidence This study provides Class II evidence that in patients with RRMS, the brain reactivity of their peripheral-blood B cells predicts clinical response to GA and IFN-β.

http://nn.neurology.org/cgi/content/short/8/3/e980?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - March 11, 2021 Category: Neurology Authors: Tacke, S., Braune, S., Rovituso, D. M., Ziemssen, T., Lehmann, P. V., Dikow, H., Bergmann, A., Kuerten, S. Tags: Autoimmune diseases, Class II, Multiple sclerosis Article Source Type: research